(Non-Hispanic Black ¼ 39 [58%]; Non-Hispanic White ¼ 63 [22%]) insurance payor status also differed among groups (P < 0.05). There were no statistically significant differences between races or insurance payor status (Medicaid versus private) with respect to medications, radiologic imaging, or laboratory testing completed in the ED (Table 2). Nearly all patients in each race group were discharged from the ED. CONCLUSIONS: Race and insurance payor status does not appear to impact the evaluation and treatment of children and adolescents with Crohn’s disease in the ED setting. P-033 YI Patients With Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis Kinnucan Jami 1 , Tomal Justin 1 , Rubin David 2 1 Inflammatory Bowel Disease Center, University of Chicago, Chicago, Illinois, 2 The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, Illinois BACKGROUND: Diverticulosis is common in patients after age 60, with a prevalence of up to 40%. Studies outside the United States (U.S.) have described a lower prevalence of diverticular disease in patients with inflammatory bowel disease (IBD) than in non-IBD. The aim of this study was to assess the prevalence and risk factors for diverticulosis in ulcerative colitis (UC) in a US tertiary center. METHODS: We performed a retrospective review in patients over 50 years of age who underwent screening or surveillance colonoscopy from January 2006 to December 2013. Pathology was reviewed for all patients to eliminate cases of segmental colitis associated with diverticula (SCAD). We first assessed the prevalence of diverticulosis in UC patients compared to patients without IBD. Then we performed a nested case-control study comparing UC patients with diverticulosis (cases) to UC patients without diverticulosis (controls) to identify clinical predictors (disease extent or disease duration) of diverticulosis. Cases were matched 1:1 fashion based on age and gender. Cases were excluded if there was lack of data or a matched control. Statistical analysis included a Student’s t-test, Chi-squared test, relative risk (RR) and adjusted RR using logistic regression. RESULTS: We identified 573 UC patients and 16,695 patients without IBD who underwent colonoscopy. 25.1% of UC patients had diverticulosis, and 46.7% of non- IBD patients had diverticulosis, P < 0.01. UC patients were younger (61.1 years versus 62.8 years, P < 0.01) and less likely to be female (46.3% versus 59.4%, P < 0.01). On univariate analysis the RR of diverticulosis ¼ 0.56 (95% CI, 0.49–0.64). On multivariate analysis adjusting for age and gender, RR of diverticulosis ¼1.03 (95% CI, 1.02–1.03). In the nested case-control study, 118 patients with UC with diverticulosis (cases) were matched to 118 patients with UC without diverticulosis (controls). The mean age of cases was 65.1 years (SD 8.9 year), and 42.3% were female, this was similar in the control group. The majority of diverticula were limited to the sigmoid/descend- ing colon (68.6%). There were no differences between cases and controls in disease duration (16.7 year versus 18.7 year, P ¼ 0.27) or extent of disease (pancolitis 50% versus 60.1%, P ¼ 0.24). CONCLUSIONS: In this US-based study, UC patients had similar rates of diverticulosis as non-IBD patients undergoing screening or surveillance colonoscopy. There were no identified predictors for the development of diverticulosis in patients with UC. These results are different than previously reported data in IBD patients in other countries and may represent unique dietary factors that contribute to the development of diverticulosis. P-034 Intensive Granulocyte-monocyte Adsorptive Apheresis Twice a Week for the Treatment of Steroid-naïve Ulcerative Colitis Miyakawa Maki, Tanaka Hiroki, Sakemi Ryosuke, Nasuno Masanao, Motoya Satoshi, Imamura Akimichi IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan BACKGROUND: Intensive granulocyte-monocyte adsorptive apheresis (GMA) admin- istered twice a week for the treatment of ulcerative colitis (UC) achieves remission more effectively and faster than weekly administration. However, there are relatively few reports regarding intensive GMA for the treatment of steroid-naïve UC patients. The objectives of this study were to investigate the efficacy of GMA for Japanese steroid-naïve UC patients, and to identify clinical predictors of remission in these patients after GMA treatment. METHODS: We retrospectively analyzed the data of active UC patients who received intensive GMA treatment at the IBD Center, Sapporo Kosei General Hospital from April 2010 to April 2014. We excluded patients with a Lichtiger clinical activity index (CAI) score of #4 and those who received additional medical treatments within 1 week before or after GMA treatment. GMA was performed using the Adacolumn (JIMRO, Takasaki, Japan). Each patient received GMA twice a week for 5 weeks with a maximum of 10 treatments. The efficacy of GMA treatment was evaluated based on the decrease in the Lichtiger CAI. Clinical remission was defined as a CAI score of #4 within 10 GMA treatments. We investigated the remission rate and time required for remission in UC patients who received GMA treatment classified by steroid response (steroid-naïve, steroid-dependent, and steroid-resistant). RESULTS: For the 78 patients (25 females, 53 males; mean age, 42.5 years) analyzed, the mean duration of disease was 5.7 years before the intensive GMA treatment and the mean CAI score was 9.6 at baseline. We classified 44, 29, and 5 patients as pan- colitis type, left-sided colitis type, and proctitis type UC, respectively. In terms of steroid response, 32, 30, and 16 patients were classified as steroid-naïve, steroid- dependent, and steroid-resistant, respectively. Of all patients, clinical remission was achieved in 42 (54%) with a mean time to remission of 15.0 days. Clinical remission of steroid-naïve, steroid-dependent, and steroid-resistant patients was achieved in 18 (56%) with a mean time of 16.2 days, 16 (53%) with a mean time of 14.8 days, and 8 (50%) with a mean time of 12.8 days. The remission rates and times to remission were not statistically significant between the steroid-naive, steroid-dependent, and steroid-resistant groups. Of the steroid-naïve patients, age was a statistically signif- icant predictor of remission (the mean ages of the remission and non-remission groups were 38.4 years and 51.8 years respectively, P ¼ 0.030). In particular, of the 20 steroid-naïve patients aged #50 years, clinical remission was effectively achieved in 15 (75%). CONCLUSIONS: In UC patients who underwent intensive GMA treatment, the remission rates and times to remission were not statistically significant among the different steroid responses. Therefore, intensive GMA treatment was found to be as effective for steroid-naive patients as it is for steroid-dependent and steroid-resistant patients. However, in the case of steroid-naive patients, a younger age might be suggested as a possible predictor of remission. P-035 Characteristics and Behavior of Elderly-Onset Inflammatory Bowel Disease: A Multi-Center U.S. Study Hou Jason 1 , Feagins Linda 2 , Waljee Akbar 3 1 Baylor College of Medicine, Houston, Texas, 2 Dallas VA Medical Center, Dallas, Texas, 3 University of Michigan, Ann Arbor, Michigan BACKGROUND: Several European studies have highlighted potential differences in inflammatory bowel disease (IBD) distribution and disease course between adult- onset and elderly-onset IBD. However, there is a paucity of studies comparing adult- and elderly- onset Crohn’s disease (CD) and ulcerative colitis (UC) populations in the U.S. The aim of this study was to compare disease characteristics and behavior of adult- and elderly- onset IBD in a multi-center U.S. study. METHODS: We reviewed the medical records of patients with IBD seen at 3 VA medical centers between 1999 and 2009 (Houston VA and Ann Arbor VA) and 1999 to 2014 (Dallas VA). Chart review was performed to identify and confirm patients with IBD and extract data regarding IBD type, behavior, location, age at, sex, and race. IBD characteristics and behavior were classified according to the Montreal Classification. Patients were classified based on age at IBD diagnosis as adult onset (18–64 years of age) or elderly onset (≥65 years of age). Statistical analyses were performed using Chi square analyses and Fisher’s exact test for discrete variables and t-tests for continuous variables. Univariate and multivariate logistic regression adjusting for race, gender, and IBD type were performed. RESULTS: A total of 1,665, patients were confirmed to have IBD based on chart review and included in the analyses, including 724 CD, 876 UC and 65 IBD unclassified patients. The cohort was 92% male, and 83% of those with identifiable race were non- Hispanic Caucasian. Males were diagnosed at a later age then females, 46.89 (SD 0.45) versus 35.62 (SD 1.09) years of age, P < 0.001. 272 patients were ≥ 65 years of age at IBD diagnosis, and 1,393 patients were <65 years of age at IBD diagnosis. After adjust- ing for IBD type and gender, Caucasians were more likely than non-Caucasians to have elderly- onset IBD (aOR 2.26, 95% CI, 1.36–3.76). Patients with UC were more likely than CD patients to have elderly- onset IBD (aOR 1.50, 95% CI, 1.11–2.03). Compared to patients with adult- onset CD, patients with elderly onset CD were more likely to have isolated colonic disease (45% versus 32%, P ¼ 0.048) and non-stricturing, non-pene- 2014 IBD Abstracts S40